RBC Capital Reiterates Outperform on Merck & Co, Maintains $142 Price Target

RBC Capital analyst Trung Huynh has reiterated an Outperform rating on Merck & Co (NYSE: MRK) and has maintained a price target of $142 for the stock. No additional financial figures or strategic changes were mentioned in the article.